BRCA1 and neoplasm: Overall, the results from this exploratory biomarker analysis of the NEOTALA study support the central role of BRCA mutations in tumor pathobiology in patients with germline BRCA1/2-mutated TNBC and the value of assessing germline BRCA mutational status for molecular eligibility for talazoparib in this indication.